|Bid||61.00 x 1400|
|Ask||65.51 x 800|
|Day's Range||63.50 - 64.30|
|52 Week Range||45.81 - 72.83|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||20.21|
|Earnings Date||Mar 30, 2020 - Apr 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||90.00|
If you own shares in BioSpecifics Technologies Corp. (NASDAQ:BSTC) then it's worth thinking about how it contributes...
BioSpecifics Technologies (BSTC) is a biopharmaceutical company. It is best known as the originator of collagenase-based therapies currently used to treat twelve clinical indications, explains Douglas Gerlach, editor of SmallCap Informer.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Today we will run through one way of estimating the intrinsic value of BioSpecifics Technologies Corp. (NASDAQ:BSTC...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- 15% year-over-year increase in royalty revenues for XIAFLEX® - BLA filing of XIAFLEX® for treatment of cellulite submitted to FDA in September 2019 LYNBROOK, N.Y. , Nov. 8, 2019 /PRNewswire/ -- BioSpecifics ...
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
LYNBROOK, N.Y., Oct. 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that Jennifer Chao has been appointed chairperson of its board of directors, effective immediately. "Jenn's counsel as chairperson of our board will be instrumental as we seek to unlock new opportunities to generate value for all our stakeholders. BioSpecifics has accomplished significant milestones in the last few years and now, as we usher the company into its next phase of growth, her life sciences industry expertise will bring an elevated level of strategy, execution and focus," said J. Kevin Buchi, chief executive officer of BioSpecifics.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
BioSpecifics (BSTC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics. "We are extremely pleased to have Kevin join BioSpecifics as chief executive officer. The board of directors believes that Kevin's diversified life sciences leadership experience and business acumen will drive transformative vision and strategy for generating both near- and long-term shareholder value," said Jenn Chao, Chair of the Executive Search Committee.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.